Skip to main content
Signal8

Tessera Defense & Homeland Security Inc. (HLSQ)

Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.

Sector: Services-Prepackaged Software

Industry: Biotechnology

Tessera Defense and Homeland Security Inc logo

Tessera Defense and Homeland Security Inc

OTC:HLSQHealthcare
AH+0.00%$0.0244
Close$0.0244+8.93%
Mkt Cap$634K
EV-
Float10.01M
O/S26M
VOL297K sh
$ Vol$7K
RVOL0.22×
Inst Own0.6%
SI0.9%
Net Cash/Sh-
Dilution
Tessera Defense and Homeland Security Inc logoOTC:HLSQAH$0.0244+0.00%
FormDescription
NT 10-Q
SEC Filing
13G/A
Beneficial Ownership Report (Amended)
8-K
8-K
CURRENT REPORT
8-K
CURRENT REPORT
DEFA14A
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A
DEFINITIVE ADDITIONAL MATERIALS
8-K
DEF 14A
DEFINITIVE PROXY STATEMENT
13D/A
13G
Beneficial Ownership Report
8-K
8-K
CURRENT REPORT
PRE 14A
PRELIMINARY PROXY STATEMENT
8-K
8-K
13D
8-K
CURRENT REPORT
13D/A
8-K
CURRENT REPORT
8-K
CURRENT REPORT
8-K/A
AMENDMENT NO. 1 TO FORM 8-K
8-K
CURRENT REPORT
8-K
CURRENT REPORT
13G/A
Beneficial Ownership Report (Amended)

1-25 of 584

…
    Tessera Defense & Homeland Security Inc. (HLSQ) SEC Filings | Signal8